AstraZeneca PLC
Most Recent
AstraZeneca Resumes COVID-19 Clinical Trials in U.K., Stock Up
Operation Warp Speed Has Invested Billions in Potential COVID-19 Vaccines
AstraZeneca Halts COVID-19 Vaccine Study After Unexplained Illness
AstraZeneca Secures Deal With Australia for COVID-19 Vaccine
Pfizer Soars Due to Hopes about a Coronavirus Vaccine
Pfizer (NYSE:PFE) stock rose 2.4% in pre-market trading at 7:51 AM ET today. The company’s experimental COVID-19 vaccine showed positive results.
AstraZeneca Rises on Its Earnings Beat
AstraZeneca (AZN) reported its second-quarter earnings results on July 25. The stock is already up 6.39% on the day and is trading close to $42.91.
How AstraZeneca Is Advancing Its Oncology Portfolio in 2019
On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.
AstraZeneca’s Lynparza Continues to Dominate
In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.
Tagrisso: AstraZeneca’s Top-Selling Drug in Q1
AstraZeneca’s (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.
How Are AstraZeneca’s Revenues Trending in 2019?
On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.
What Analysts Recommend for Merck and AstraZeneca in June
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
AstraZeneca’s Imfinzi Maintains Strong Growth in Q1
Imfinzi earned $64 million from ex-US markets in the first quarter, while Japan alone accounted for $34 million of these sales.
AstraZeneca’s Tagrisso Sees the Fastest Growth in Q1
In the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis and 92% on a CER (constant exchange rate) basis.
What AstraZeneca Expects for EPS in Fiscal 2019
In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for core EPS of $3.50–$3.70 in fiscal 2019.
AstraZeneca Reiterates Its Fiscal 2019 Revenue Guidance
In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product sales.
What Analysts Recommend for AstraZeneca after Its Q1 Results
AstraZeneca (AZN) announced its first-quarter results on April 26. Analysts’ average target price of $46.10 implies a 21.35% upside for AstraZeneca stock.
AstraZeneca’s Oncology Portfolio: Growth Trends in 2019
During AstraZeneca’s fourth-quarter presentation, it highlighted the potential of Tagrisso to become the highest-earning drug in its portfolio in 2019.
PFE or AZN: Comparing Their Earnings Growth in 2019
On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92.
PFE or AZN: Comparing Revenue Growth in 2019
On its fourth-quarter earnings conference call, Pfizer (PFE) guided for the strong performances of its key brands.
What Are Analysts Recommending for PFE and AZN?
On April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37.
What are AstraZeneca’s Key Growth Drivers?
In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis.
A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt
In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported effective tax rates of 3% and $15.98%, respectively.
Comparing AstraZeneca’s and Eli Lilly’s Dividends
In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported dividends per share of $1.40 and $2.25, respectively.
AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.
What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth
In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.
Analysts’ Recommendations for AstraZeneca and Eli Lilly
Most analysts recommend “buy” for AstraZeneca and Eli Lilly.
What Are Merck’s Key Growth Drivers for 2019?
Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal health businesses as its key growth drivers in 2018.
How Is AstraZeneca Faring in Chinese Markets?
In the first nine months of 2018, AstraZeneca (AZN) reported revenues worth $2.85 billion from China, which is a YoY rise of 33% on an actual basis and 27% on a CER (constant exchange rate) basis.
Why Has AstraZeneca’s Stock Price Increased in 2018?
On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.
A Look at Merck’s Diabetes and Women’s Health Business
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.
How JNJ’s Invega Sustenna and Risperdal Consta Performed
Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.
Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
On October 2, Johnson & Johnson announced the completion of the divestiture of its LifeScan business to Platinum Equity for ~$2.1 billion.
AstraZeneca: Dividend Overview and Recent Developments
Of the five analysts tracking AstraZeneca in September, three recommended a “strong buy.” One analyst recommended a “buy,” and one analyst recommended a “hold” rating.
Here’s What’s Driving Investor Interest in Immunomedics
Clinical stage biopharmaceutical company Immunomedics (IMMU) is currently focused on advancing several research programs.
A Look at Shire’s Valuation on September 19
Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.
Novartis to Divest Portions of Sandoz US to Aurobindo
Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.
EC Approves GSK’s Nucala for Children with Severe Asthma
On August 30, GlaxoSmithKline (GSK) announced that the EC approved Nucala for pediatric patients with severe refractory eosinophilic asthma.
Analyzing Eli Lilly’s Q2 2018 Revenue Trend
Eli Lilly and Company surpassed Wall Street analysts’ estimates in the second quarter and reported a 9% YoY (year-over-year) rise in revenue.
Novartis’s Alcon in Q2 2018
Alcon, Novartis’s (NVS) eye care business, reported a 7% growth YoY (year-over-year) in revenues to ~$1.82 billion during Q2 2018.
Novartis’s Sandoz in Q2 2018
Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.
AstraZeneca’s Oncology Product Sales: 40% Growth
Zoladex’s sales grew 4.0% to $192.0 million, and Arimidex’s sales grew 2.0% to $57.0 million during the second quarter.
Understanding AstraZeneca’s Geographic Segment Performance
AstraZeneca’s sales in China surged by 26.0% to $868.0 million in the second quarter.
How Did AstraZeneca’s CVRM and Respiratory Products Perform?
Brilinta’s sales increased by 13.0% to $316.0 million, and Farxiga’s sales grew 34.0% to $340.0 million in the second quarter.
Novartis’s SOLAR-1 Trial Met Primary Endpoint
Novartis (NVS) announced on August 23 that its SOLAR-1 trial evaluating alpelisib combined with fulvestrant has met its primary endpoint.
Tecentriq Could Boost Roche’s Revenue Growth in 2018 and Beyond
Roche’s (RHHBY) Tecentriq generated revenues of 320.0 million Swiss francs in the first half compared to 237.0 million Swiss francs in the first half of 2017.
Gauging Analysts’ Expectations for Novavax and Peers in August
Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.
What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.
Merck: Lynparza and Lenvima Might Be Key Oncology Assets
On May 8, Merck (MRK) and AstraZeneca (AZN) managed to secure approval from the European Medicines Agency for Lynparza as maintenance therapy.
How Merck’s Oncology Drugs Have Performed
In the second quarter of 2018, Merck’s (MRK) Emend generated revenues of $148.0 million compared to $143.0 million in the second quarter of 2017.
How Is Merck’s Diabetes and Women’s Health Business Positioned?
In the second quarter of 2018, Merck’s (MRK) Januvia and Janumet generated revenues of $949 million and $585.0 million, respectively.
Eli Lilly’s Q2 2018 Earnings: Key Developments
Eli Lilly (LLY) announced a potential initial public offering for Elanco, which is its animal health business.
How Baxter International Fared in the Second Quarter
Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.
What Analysts Think about AstraZeneca and Peers in July
AstraZeneca (AZN) is expected to incur research and development expenses of $1.26 billion in Q2 2018 as compared with $1.28 billion in Q2 2017.
GlaxoSmithKline’s Q2 2018 Earnings: Analysts’ Estimates
Analysts are estimating that GlaxoSmithKline’s (GSK) revenues will decrease 1.5% to 7.2 billion pounds in Q2 2018.
Why Advaxis Stock Is Soaring Today
Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.
An Update on JNJ’s Neuroscience Business after Q1 2018
In Q1 2018, Johnson & Johnson’s (JNJ) Neuroscience business reported revenues of $1.6 billion compared to $1.5 billion in Q1 2017.
NVO’s Victoza and Ozempic Could See Steady Growth in 2018
In June, Novo Nordisk presented the post hoc analysis of the SUSTAIN 7 trial.
A Look at Novo Nordisk’s Financial Position
Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.
AstraZeneca’s Imfinzi and Lynparza Receive Approval in Japan
AstraZeneca (AZN) received two key regulatory approvals in Japan this week, one for Imfinzi and the other for Lynparza.
Pfizer Stock: Trade War Affects Healthcare Products
Pfizer’s stock price was nearly flat on June 27 at the closing price of $36.38. Pfizer’s stock price has increased ~0.4% in the past week.
How Pfizer’s Business Segments Have Performed
As discussed, Pfizer’s (PFE) business is divided into two business segments, Innovative Health and Essential Health.
How the Trade War Could Affect the US Healthcare Industry
By the end of June 25, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 were down around 2.1%, 1.3%, and 1.4%, respectively.
Tesaro Stock Up over 16% on Rumors of Acquisition by Roche
Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.
What’s in AstraZeneca’s Research Pipeline for Fiscal 2019
In the second half of fiscal 2018, major news is expected for indications in diabetes, anemia, COPD (chronic obstructive pulmonary disease), and lupus in AstraZeneca’s (AZN) pipeline.
A Look At AstraZeneca’s Research Pipeline
Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter.
Analysts’ Recommendations for GlaxoSmithKline in May
GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.
A Closer Look at Novartis’s Innovative Medicine Business
Novartis’s (NVS) Innovative Medicines business, which comprises its Novartis Pharmaceuticals and Novartis Oncology products, reported revenue of $8.4 billion in the first quarter, with operating revenue and foreign exchange contributing 6% growth each.
How Did AstraZeneca’s Respiratory Segment Perform in Q1 2018?
In emerging markets, Symbicort grew 14.0% to $128.0 million on the back of 38.0% growth in the China market to $66.0 million.
The Performance of AstraZeneca’s Pulmicort, Daliresp, and Tudorza
AstraZeneca’s (AZN) Pulmicort witnessed a 3.0% increase in sales to $346.0 million in the first quarter.
Analyzing AstraZeneca’s CVRM Performance
Sales of Brilinta increased 31.0% to $293.0 million in the first quarter.
AstraZeneca’s Farxiga Sees Impressive 44% Growth in Q1 2018
AstraZeneca’s (AZN) Farxiga generated product sales of $299.0 million, an increase of 44.0%.
How AstraZeneca’s Lung Cancer Products Performed in Q1 2018
Tagrisso, approved in more than 75 countries, registered an increase in sales of 98.0% to $338.0 million, driven by higher testing rates in Japan and the US.
A Look at the Upside Potential of AstraZeneca Stock
Four of the six analysts covering AstraZeneca (AZN) gave the stock a “buy” or higher rating, and two analysts gave it a “hold” rating.
BMY’s CheckMate 227 Trial Highlighted Importance of TMB Biomarker
Bristol-Myers Squibb (BMY) has played a major role in positioning the tumor mutational burden (or TMB) as a potential new biomarker across multiple tumor types.
Opdivo May Witness Decline in This Target Patient Population
At the end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication.
A Performance Review of Merck’s Diversified Products
Merck & Company’s Singulair, a drug for the prevention and treatment of asthma, reported revenue of $175 million in Q1 2018.
Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?
Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease.
AstraZeneca’s 1Q18 Estimates: Respiratory Products
AstraZeneca’s (AZN) growth platforms include its Respiratory segment, which is expected to report growth in revenue during 1Q18.
AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.
How Lynparza Performed in 1Q18
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza.
What Analysts Recommend for Merck and Peers in May
In 1Q18, Merck (MRK) reported revenues close to $10.0 billion, which is a year-over-year (or YoY) rise of around 6%.
Merck and AstraZeneca Announced EMA Approval for Lynparza
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
How Merck’s Human Vaccines Business Performed in 1Q18
In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion.
GlaxoSmithKline’s Pharmaceutical Business in 1Q18
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products.
Novo Nordisk’s Victoza Could See High Growth in 2018
In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner.
Analysts’ Recommendations for Novartis on April 17
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16.
Updates on AbbVie’s AndroGel, Lupron, and Kaletra
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter.
Barclays Downgrades Pfizer Stock and Cuts Price Target
On April 5, 2018, Barclays (BCS) updated its recommendations for some leading US pharmaceutical companies.
What Boosted Merck’s Stock Price on April 9
On April 9, 2018, Merck (MRK) stock rose ~4.4% in early trading and ~2.7% during the day.
How AstraZeneca’s 1Q18 Shook Out
AstraZeneca stock has fallen ~1.2% in 1Q18, and its stock has risen ~2.1% YTD (year-to-date) as of April 6, 2018.
Assessing the Performance of Novartis Stock in 1Q18
Novartis stock has fallen ~7.0% in 1Q18, and it’s fallen 4.5% YTD (year-to-date) as of April 6, 2018.
How GlaxoSmithKline Stock Performed in 1Q18
GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.
Understanding FibroGen’s Research Pipeline
Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.
Why GlaxoSmithKline Stock Rose in the Week Ended March 29
On March 29, 2018, GlaxoSmithKline (GSK) was trading at $39.42, which represented a ~13% rise from its 52-week low of $34.52.
How Did Novartis’s Established Medicines Segment Perform in 2017?
In 4Q17, Novartis’s (NVS) Galvus generated revenues of $327 million, which is ~10% growth on a year-over-year (or YoY) basis and 5% growth quarter-over-quarter.
How Is Novartis’s Xolair Positioned after 4Q17?
In 4Q17, Novartis’s (NVS) Xolair generated revenues of $247 million, which reflected ~14% growth on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.
How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?
In 4Q17, Novartis’s (NVS) Afinitor generated revenues of $407 million compared to $391 million in 4Q16, which reflected ~4% growth on a year-over-year (or YoY) basis and ~5% growth quarter-over-quarter.
Must-Know Developments for Ionis Pharmaceuticals in 2018
On February 20, 2018, Ionis announced that the company has licensed the drug IONIS-AZ5-2.5Rx to AstraZeneca (AZN).